At the news
? NEUTRALIMPACT 3/10 6-K filed May 7, 2026 at 09:00 ET
Alpha Tau announced the first patient treated in Italy with its Alpha DaRT therapy for pancreatic cancer, a feasibility and safety study at the University of Verona's Pancreas Institute. The milestone expands the company's global pancreatic cancer program but represents an early-stage clinical update with no near-term revenue implications.
- First Alpha DaRT pancreatic cancer patient treated in Italy under protocol CTP-PANC-03
- Study plans to enroll up to 15 patients with locally advanced pancreatic cancer at a single center
- First Alpha DaRT pancreatic protocol to permit both endoscopic ultrasound (EUS) and percutaneous delivery
- Follows first European patient treated in April 2026 in France's ACAPELLA trial and ongoing U.S. IMPACT trial
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access